DS
KNSA icon

David Shaw’s Kiniksa Pharmaceuticals KNSA Stock Holding History

David Shaw’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.4M Sell
569,756
-389,501
-41% -$20.2M 0.02% 941
2026
Q1 		$46.2M Sell
959,257
-282,364
-23% -$12.5M 0.03% 692
2025
Q4 		$51.2M Buy
1,241,621
+107,435
+9% +$4.31M 0.03% 684
2025
Q3 		$44M Buy
1,134,186
+342,881
+43% +$11.1M 0.02% 721
2025
Q2 		$21.9M Buy
791,305
+393,560
+99% +$10M 0.02% 978
2025
Q1 		$8.83M Buy
397,745
+77,738
+24% +$1.6M 0.01% 1489
2024
Q4 		$6.33M Sell
320,007
-990
-0.3% -$22.6K ﹤0.01% 1796
2024
Q3 		$8.02M Buy
320,997
+151,349
+89% +$3.69M 0.01% 1582
2024
Q2 		$3.17M Sell
169,648
-52,205
-24% -$978K ﹤0.01% 2225
2024
Q1 		$4.38M Sell
221,853
-82,752
-27% -$1.62M ﹤0.01% 1991
2023
Q4 		$5.34M Sell
304,605
-12,914
-4% -$212K ﹤0.01% 1855
2023
Q3 		$5.52M Buy
317,519
+78,919
+33% +$1.33M 0.01% 1729
2023
Q2 		$3.36M Sell
238,600
-1,188
-0.5% -$15.9K ﹤0.01% 2197
2023
Q1 		$2.58M Buy
239,788
+2,343
+1% +$30.9K ﹤0.01% 2491
2022
Q4 		$3.56M Buy
237,445
+125,274
+112% +$1.82M ﹤0.01% 2408
2022
Q3 		$1.44M Buy
112,171
+69,243
+161% +$789K ﹤0.01% 3293
2022
Q2 		$416K Buy
+42,928
New +$401K ﹤0.01% 4205
2022
Q1 		– Sell
-12,317
Closed -$145K – 5760
2021
Q4 		$145K Buy
+12,317
New +$151K ﹤0.01% 4978
2021
Q1 		– Sell
-50,089
Closed -$885K – 4276
2020
Q4 		$885K Sell
50,089
-52,297
-51% -$919K ﹤0.01% 3094
2020
Q3 		$1.57M Buy
102,386
+53,004
+107% +$995K ﹤0.01% 2558
2020
Q2 		$1.26M Buy
+49,382
New +$1.03M ﹤0.01% 2768
2019
Q3 		– Sell
-26,134
Closed -$354K – 3919
2019
Q2 		$354K Sell
26,134
-69,122
-73% -$1.07M ﹤0.01% 3243
2019
Q1 		$1.72M Buy
95,256
+85,714
+898% +$1.66M ﹤0.01% 2267
2018
Q4 		$268K Buy
+9,542
New +$199K ﹤0.01% 3413

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

David Shaw's KNSA Position: Q2 2026 in Review

David Shaw reduced its Kiniksa Pharmaceuticals (KNSA) stake by 41% in Q2 2026, selling an estimated $20.2M and leaving 569,756 shares worth $36.4M. The position accounts for 0.02% of the portfolio, ranked #941.

David Shaw first reported a position in KNSA in Q4 2018 and has held it in 24 quarters since. The position peaked at $51.2M in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • David Shaw held 569,756 shares of Kiniksa Pharmaceuticals worth $36.4M as of Q2 2026.
  • David Shaw sold 389,501 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $20.2M.
  • Kiniksa Pharmaceuticals made up 0.02% of David Shaw's portfolio in Q2 2026, its #941 holding.
  • David Shaw first reported a position in Kiniksa Pharmaceuticals in Q4 2018 and has held it in 24 quarters since.
  • David Shaw's Kiniksa Pharmaceuticals position peaked at $51.2M in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.